Sb 334867

After 3-wk of LDA, mice began to be handled for habituation and systemic injections. The selective OX1R antagonist, SB-334867 (SB, Tocris), was dissolved in 2% DMSO in 25% (2-Hydroxypropyl)-β-cyclodextrin (Sigma) and 0.9% saline; the OX2R antagonist TCS-OX2-29 (TCS, Tocris) (Huang et al., 2010 (link); Plaza-Zabala et al., 2013 (link)) was dissolved in 0.9% saline. Animals were injected, intraperitoneally (i.p.), 30-min prior to the drinking sessions. Subjects received either 0, 0.3, 1, 3 or 10-mg/kg-body-weight of SB, or 3 or 10-mg/kg-body-weight of TCS at a volume of 10-ml/kg (similar to previously used volumes, e.g. Olney et al., 2015 (link)). The selected SB doses were lower than what was previously used because we hypothesized mice drinking alcohol-quinine would be more sensitive to the effects of OX1R inhibition. Each given dose was injected twice (on different test days) and averaged per mouse; injections were counter-balanced with their vehicle across test days and mice using a Latin Squares design. There was at least one drinking session day between drug treatments to limit the impact of carryover effects after drug treatment, and drinking levels returned to baseline on these untreated days (not shown). Also, no more than two injections were performed in a given week (Fig. 1). The SacQ group was treated with either 0- or 3-mg/kg-body-weight of SB.